Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Enterprise Value (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Enterprise Value data on record, last reported at -$737.1 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 87.98% year-over-year to -$737.1 million; the TTM value through Dec 2025 reached -$737.1 million, down 87.98%, while the annual FY2025 figure was -$737.1 million, 87.98% down from the prior year.
  • Enterprise Value reached -$737.1 million in Q4 2025 per OCUL's latest filing, down from -$344.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$66.6 million in Q2 2023 and bottomed at -$737.1 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$264.2 million, with a median of -$193.9 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: skyrocketed 50.49% in 2023, then plummeted 590.16% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$164.2 million in 2021, then surged by 37.68% to -$102.3 million in 2022, then crashed by 91.55% to -$196.0 million in 2023, then plummeted by 100.1% to -$392.1 million in 2024, then plummeted by 87.98% to -$737.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$737.1 million in Q4 2025, -$344.8 million in Q3 2025, and -$391.1 million in Q2 2025.